ApoB and lipoprotein(a): risk markers beyond the standard lipid panel

An ApoB test counts the number of atherogenic particles circulating in your blood, and a lipoprotein(a) test — usually written Lp(a) — measures a distinct, largely inherited particle that a standard lipid panel does not report at all. Both exist because LDL cholesterol, the number most people are used to seeing on a lab report, has real limits: it estimates the amount of cholesterol carried inside particles rather than counting the particles themselves, and it says nothing about Lp(a).

This article covers what ApoB and Lp(a) are, why ApoB can move independently of LDL-C, what the units on your report mean, and who guidelines say benefits from either test. It does not re-explain what LDL and HDL cholesterol are or how “good” and “bad” cholesterol work — that ground is covered in our guide to LDL and HDL cholesterol. It also does not cover screening schedules or drug dosing, both of which are decisions for a clinician.

ApoB and Lp(a) at a glance

Why ApoB and LDL-C can disagree

LDL-C is a calculated or measured estimate of how much cholesterol is packed into LDL particles. ApoB, by contrast, reflects the number of particles, because each LDL particle (and each VLDL, IDL and Lp(a) particle) carries exactly one ApoB molecule. According to MSD Manuals, apoB measurement includes all these atherogenic particles, including remnants and Lp(a), and provides similar information to a direct LDL particle count.

Most of the time, particle number and particle cholesterol content move together, so LDL-C and ApoB tell a similar story. They diverge — a pattern usually called discordance — when particles are smaller and more cholesterol-depleted than average. In that situation, a person can carry a large number of small, cholesterol-poor LDL particles while their LDL-C looks unremarkable, because LDL-C only sees the cholesterol, not the particle count. MSD Manuals notes that measuring LDL particle number or ApoB is useful specifically in patients with elevated triglycerides and metabolic syndrome, situations that commonly produce this smaller, more numerous particle pattern.

Discordance is most likely to matter in a few recurring situations: high triglycerides, type 2 diabetes, metabolic syndrome, and when LDL-C already looks close to a treatment target but overall cardiovascular risk still seems higher than expected.

Lp(a): mostly fixed by genetics, checked once for most people

Lp(a) behaves differently from every other lipid measured in a routine panel. According to MedlinePlus, genes largely control how much Lp(a) a person makes, levels reach an adult baseline in early childhood, and that level tends to stay about the same for the rest of life — which is also why diet and exercise generally do not change it. Because the result does not drift the way LDL-C or triglycerides can, most people only need it measured once; a clinician may order it again only if there is a specific reason to expect the earlier result was misleading or incomplete.

Units: do not convert between them yourself

Lp(a) results are reported either in nanomoles per liter (nmol/L) or in milligrams per deciliter (mg/dL), and the unit depends on the laboratory. These two units are not interconvertible by a single fixed formula, because Lp(a) particles vary in size from person to person, and a mass-based unit (mg/dL) and a molar unit (nmol/L) do not track each other consistently across that variation. Testing.com states plainly that the conversion between the two units is not straightforward and that a result in one unit cannot be reliably converted to the other with a simple formula. Read your own report’s unit and its own reference interval; do not compare a number in one unit against a range printed for the other.

ApoB is reported in mg/dL or in g/L, depending on the laboratory. As with any biomarker, compare your result only against the reference interval printed on the same report, in the same unit.

Who benefits from testing, per the guidelines

The European Society of Cardiology and European Atherosclerosis Society jointly issue guidance on managing dyslipidaemias, and the same two societies published a dedicated 2022 consensus statement on Lp(a). Testing.com summarizes the substance of that guidance in patient-facing terms: Lp(a) measurement is recommended at least once for adults, with priority given to people who have a personal or family history of early atherosclerotic cardiovascular disease or familial hypercholesterolemia.

MedlinePlus describes a similar, narrower set of reasons a clinician might order an Lp(a) test: a family history of early heart or blood vessel disease, high LDL cholesterol that has not responded as expected to treatment, cardiovascular disease despite otherwise normal cholesterol and triglyceride results, signs of familial hypercholesterolemia, or more than one heart attack or artery-opening procedure.

For ApoB, MSD Manuals frames the AHA/ACC approach to cardiovascular risk assessment: elevated ApoB is listed among the risk-enhancing factors that guideline considers, alongside elevated Lp(a), persistently high LDL-C, and persistently high triglycerides, and ApoB or LDL particle number measurement is described as useful specifically when triglycerides are elevated or metabolic syndrome is present.

None of this amounts to a rule that everyone should have either test, and no guideline cited here sets a testing interval beyond the “at least once” language for Lp(a). Whether either test is useful for you, and how to act on the result, is a decision for your clinician based on your full risk picture.

What a high result does — and does not — mean

A high ApoB or high Lp(a) result is one more input into an overall cardiovascular risk assessment; it is not, by itself, a diagnosis of atherosclerotic disease. The link between elevated Lp(a) and cardiovascular disease is well documented as an association across large populations, not proof that a given individual’s result will lead to disease — genetics, other risk factors and overall health all interact.

On treatment: for ApoB, the same measures that address LDL-C and triglycerides — reviewed with a clinician — are relevant, since ApoB reflects the same family of particles. For Lp(a), there is currently no medicine approved specifically to lower it. Management instead focuses on the other modifiable risk factors a person carries — LDL cholesterol, blood pressure, smoking and similar — because those remain adjustable even when Lp(a) itself is not. This reflects the current state of approved treatment; it is not a comment on what may become available in the future, and any decision about whether or how to act on an Lp(a) or ApoB result belongs with a clinician who can see the rest of your risk profile.

Preparation and factors that can distort results

Lp(a) needs no fasting: because the level is genetically set, it is not affected by a recent meal or drink the way LDL-C and triglycerides are. Recent acute illness or infection can still distort a single result, since Lp(a) behaves as an acute-phase reactant and can rise temporarily during illness or inflammation — mention any recent illness before the draw. Tell your provider about niacin supplements, aspirin, PCSK9 inhibitors, oral estrogen or recent alcohol, since these can modestly affect the reading, and note that Lp(a) can also shift around menopause as estrogen declines. For ApoB, follow whatever fasting instructions your laboratory gives for the lipid panel it is drawn with — fasting practice for lipid testing varies by laboratory and clinical situation rather than following one fixed rule.

When to seek help

A high ApoB or Lp(a) result is a risk factor, not a diagnosis or an emergency. New chest pain, sudden breathlessness, sudden weakness on one side of the body, or new difficulty speaking need emergency medical attention regardless of any lab result, past or pending. Separately, bring these results to a clinician’s attention if you or a close relative had a heart attack, stroke or artery disease at a young age, if familial hypercholesterolemia runs in the family, or if a clinician has told you your cardiovascular risk looks higher than your standard lipid panel would suggest.

Tracking ApoB and Lp(a) with HealthLab

Because Lp(a) is usually measured only once, and ApoB may be checked alongside a lipid panel more than once over time, keeping both results together with the rest of your bloodwork makes them easier to find later. HealthLab imports lab reports from a PDF or a photo with AI recognition, or lets you enter a result manually with its own reference range and unit, so an mg/dL or nmol/L Lp(a) value and an mg/dL or g/L ApoB value are each stored correctly rather than mixed up. Manual entry is free and unlimited, while the free tier includes one AI import to try it and unlimited AI import is part of Pro. Apple Health data and your lab results live in one app, each on its own chart, so a once-off Lp(a) result does not get lost among unrelated records. Trend charts show each biomarker over time alongside your other panels such as LDL and HDL cholesterol or triglycerides, results export as a PDF for an appointment, and additional profiles for family members come with Pro.

HealthLab organises your results and makes it easier to bring a clear history to a doctor. It does not diagnose cardiovascular disease or tell you whether a result needs treatment — that assessment stays with your clinician, alongside the rest of your heart health blood tests. If you want to talk through your results with a professional, HealthLab’s lab directory can help you find a laboratory to order further testing near you.

Frequently asked questions